Heart attack

November 25, 2017

Natural product-derived therapy for Myocardial Infarction: Hypaphorine, isolated from Caragana korshinskii Kom, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via  up-regulation of PNUTS,  25/November/2017, 3.55 pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of Nature,  by Prof Dimmler, […]
November 20, 2017

Natural product-derived therapy for attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mix encompassing Bixin and Norbixin decreases GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, and promotes heart healing via up regulation of its target gene, 20/November/2017, 8.46 am

Introduction: What they say: A recent study from Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; and Center for Systems […]
November 18, 2017

Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and Fidarestat (AF) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, attenuates diabetic nephropathy, insulin resistance and hypertension and extends life span via up regulation of its target gene, 18/November/2017, 8.03 am

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Cardiac rejuvenation, diabetic-associated complications and Hypertension: A therapeutic mix encompassing  Aspirin and […]
November 13, 2017

Cardiac rejuvenation therapy: A therapeutic mix encompassing  Victoza and Atorvastatin (VA) suppresses tumor suppressor INK4a/p16 expression, promotes cardiac repair, delays cardiac ageing and senescence, and extends life span via up regulation of its target gene, 13/November/2017, 11.35 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Cardiac rejuvenation therapy: A therapeutic mix encompassing Victoza (also known as Liraglutide) and Atorvastatin (VA)  suppresses […]